Metabolické aspekty hormonální substituční terapie u postmenopauzálních žen

Abstract

The aim of project was to evaluate which of aplication forms of estrogen replacement therapy (in daily doses 2 mg estradiol orally or 0,05 mg estradiol transderma) is better for postmenopausal women from the view of cardiovascular risk. Oral aplication was conected with favourable elevation of HDL-cholesterol level and lowering of prothrombin activator inhibitor (PAI-1). On the other side there were elevation of tigylcerides and high selective C-reactive protein (hs CRP) and lowering of tissue factor pathway inhibitor (TFPI). Transdermal therapy was conjoined with elevation of HDL-cholesterol. Other markers were not influenced by this aplication form. Transdermal estrogen replacement therapy is more favourable than oral estrogen replacement therapy from the view of cardiovascular risks. The choice of hormone replacement therapy must be strongly individual. The knowledge of level lipids and other factors of cardivascular risk, could be helpfull during choice of aplication form, dose and contents of hormone replacement therapy.